Replies to post #131356 on Biotech Values

[biomaven0]

Do you have any opinion on the other drugs in INCY's pipeline, namely the c-MET drug in Phase 1 and the IDO inhibitor in Phase 1?

Don't know much about either. They always sounded enthusiastic about their IDO drug, but given it's 1st-in-class we'll have to wait for actual data to know if their enthusiasm is justified.

At this point neither is going to drive the stock price for the foreseeable future.

Peter

[poorgradstudent]

INCY:

They gave the cMET to NVS, so I suspect that it won't be a big driver for revenues.

They sound somewhat excited about the IDO inhibitor, but they also sounded enthusiastic about the sheddase inhibitor and dropped that one after phase 2.

At the least, they do seem to be placing an emphasis on making stringent decision about what they will and won't develop. They have a couple of projects (a topical JAK inhibitor and a diabetes candidate, INCB13739) that they don't seem to be putting money into but rather waiting for someone else to work on.

For the next 3-4 years, it's really about PV/ET and RA.

[Praveen]

I don't follow YMI much but maybe people are waiting for the cyt387 data to be released soon at ASH to compare.

[jq1234]

I think so as well and INCY has nice terms on their deal with LLY IMO. I've always followed RIGL and do like fostamatinib but INCY's drug seems to have less questions at this point on the safety front and I think efficacy is reasonably comparable between the two drugs at this point.

It COULD be significant down the road, not in next 12 or even 24 months IMO. Look at RIGL's RA drug, they have been studied in more patients in phase 2 and currently in phase 3, should have results in next 6-8 months, RIGL's enterprise value currently at $230m. This should give you idea how market value other oral RA drugs at the moment. INCY's RA still in phase 2b, won't be significant value driver until it has more longer term data on more patients. Neither will VRTX's RA drug.

Ruxo topical formulation for psoriasis is interesting to me, not sure what their plan is because it is differentiated.